Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
31M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
25.7M
-
Shares change
-
+1.82M
-
Total reported value, excl. options
-
$101M
-
Value change
-
+$1.21M
-
Put/Call ratio
-
0.69
-
Number of buys
-
35
-
Number of sells
-
-18
-
Price
-
$3.91
Significant Holders of Skye Bioscience, Inc. - Common Stock, par value $0.001 per share (SKYE) as of Q3 2024
82 filings reported holding SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Skye Bioscience, Inc. - Common Stock, par value $0.001 per share (SKYE) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.7M shares
of 31M outstanding shares and own 83% of the company stock.
Largest 10 shareholders include 5AM Venture Management, LLC (9.91M shares), Versant Venture Management, LLC (2.01M shares), SPHERA FUNDS MANAGEMENT LTD. (1.56M shares), BAKER BROS. ADVISORS LP (1.43M shares), Altium Capital Management LP (1.32M shares), BlackRock, Inc. (1.19M shares), Schonfeld Strategic Advisors LLC (959K shares), Ensign Peak Advisors, Inc (900K shares), VANGUARD GROUP INC (844K shares), and Driehaus Capital Management LLC (651K shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.